C Lucanto
Overview
Explore the profile of C Lucanto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arrigo T, De Luca F, Lucanto C, Lombardo M, Rulli I, Salzano G, et al.
Diabetes Nutr Metab
. 2004 Jul;
17(2):114-9.
PMID: 15244104
Aims of this study were to investigate menarcheal age (MA) and menarcheal determinants in 25 girls with cystic fibrosis (CF) and to compare their MA with their respective mothers'. Patients'...
2.
Lombardo F, De Luca F, Rosano M, Sferlazzas C, Lucanto C, Arrigo T, et al.
Eur J Endocrinol
. 2003 Jun;
149(1):53-9.
PMID: 12824866
Objective: The loss of pancreatic beta-cells is thought to be one of the principal causes of diabetes mellitus (DM) in cystic fibrosis (CF), but the role of peripheral insulin resistance...
3.
Lucanto C, Bauer S, Hyman P, Flores A, Di Lorenzo C
Dig Dis Sci
. 2000 Aug;
45(7):1274-80.
PMID: 10961703
We wished to investigate the urodynamic characteristics and colonic motility in a group of children with severe chronic constipation and lower urinary tract symptoms. We performed colonic manometry using an...
4.
Di Lorenzo C, Lucanto C, Flores A, Idries S, Hyman P
J Pediatr Gastroenterol Nutr
. 1999 Sep;
29(3):293-6.
PMID: 10467994
Background: In earlier studies, erythromycin stimulated but octreotide inhibited gastric antral contractions, as each drug induced phase 3-like episodes. Methods: To assess the effect of erythromycin pretreatment on octreotide-induced changes...
5.
Di Lorenzo C, Lucanto C, Flores A, Idries S, Hyman P
J Pediatr Gastroenterol Nutr
. 1998 Nov;
27(5):508-12.
PMID: 9822313
Background: The somatostatin analogue octreotide has been proposed as a possible therapeutic agent in patients with abnormal gastrointestinal motility. This study was conducted to study the effects of 0.5 microg/kg...
6.
Magazzu G, Bottari M, Tuccari G, Arco A, Pallio S, Lucanto C, et al.
J Clin Gastroenterol
. 1994 Oct;
19(3):255-7; discussion 257-8.
PMID: 7806840
In our study, we evaluated whether the combination of two endoscopic abnormalities in the duodenum (the "mosaic" appearance and loss of duodenal folds) is significantly associated with duodenal villous atrophy...